Journal article
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
- Abstract:
-
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: A growing body of evidence supports the anti-cancer effect of histone deacetylase inhibitors (HDACi) in vitro, via multiple pathways, and many Phase I clinical trials have shown them to be well-tolerated in a range of malignancies. Combined therapies, including with radiation, present an exciting area of current and planned study. This review summarises the evidence to date, including pre-clinical data and clinical trials, of the anti...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- BJU international
- Volume:
- 111
- Issue:
- 4
- Pages:
- 537-542
- Publication date:
- 2013-04-01
- DOI:
- EISSN:
-
1464-410X
- ISSN:
-
1464-4096
- Source identifiers:
-
394963
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:394963
- UUID:
-
uuid:ce45922d-3bf8-4fb2-ab9a-7962f2cfb3cf
- Local pid:
- pubs:394963
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2013
If you are the owner of this record, you can report an update to it here: Report update to this record